APG-5918

DRUG2 trials

Sponsors

Ascentage Pharma Group Inc.

Conditions

AnemiaB Cell LymphomaCastrate Resistant Prostate CancerEpithelioid SarcomaGastric CancerMesotheliomaNasopharyngeal CarcinomaNon Hodgkin Lymphoma

Phase 1

Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas

Ascentage Pharma Group Inc.B Cell Lymphoma, Castrate Resistant Prostate Cancer, Epithelioid Sarcoma +6

Start: 2022-09-30End: 2025-09-30Target: 90Updated: 2022-11-16

A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Efficacy of APG-5918.

RecruitingNCT05773586

Ascentage Pharma Group Inc.Anemia

Start: 2023-03-13End: 2028-07-15Target: 105Updated: 2026-04-15